{"entity":{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","aka":[],"tldr":"Tae Won Kim is Korea's leading colorectal cancer trialist, an investigator on the fruquintinib, trifluridine/tipiracil, and anti-EGFR studies used worldwide.","summary":"Tae Won Kim is Professor of Medical Oncology at Asan Medical Center in Seoul, where he leads colorectal oncology. He is Korea's leading colorectal cancer trialist, serving on the steering committees of global metastatic colorectal cancer trials including FRESCO-2 with fruquintinib and SUNLIGHT with trifluridine/tipiracil, and on Asian anti-EGFR and KRAS studies. His publications include the FRESCO-2 trial of fruquintinib against placebo in refractory metastatic colorectal cancer. His interests are colorectal cancer, targeted therapy and clinical trials.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TW%5BAuthor%5D%20Asan%20colorectal"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["fruquintinib","trifluridine-tipiracil"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["fresco-2","sunlight"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; colorectal cancer","institutionId":"asan-medical-center","specialisms":["Colorectal cancer","Targeted therapy","Clinical trials"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kim%20TW%5BAuthor%5D%20Asan%20colorectal"}],"papers":[{"title":"Fruquintinib versus placebo in refractory metastatic colorectal cancer (FRESCO-2)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00772-9"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"},{"title":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2308795","doi":"10.1056/NEJMoa2308795"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"}]},"route":"/people/kim-tae-won/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"institution":[{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/"}],"trial":[{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/"},{"id":"sunlight","kind":"trial","name":"SUNLIGHT","route":"/trials/sunlight/"}],"paper":[{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/"},{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/"}]}}